Login to Your Account



In BioCryst's Phase IIb Study, BCX4208 Gets the Gout Out

By Catherine Shaffer


Thursday, October 6, 2011
Gout is an old-fashioned-sounding disease that many associate with aging. It is, however, a painful condition affecting 8.3 million people in the U.S., a minority of which achieve satisfactory treatment with the market-leading product, allopurinol, for reducing serum uric acid (sUA) levels. BioCryst Pharmaceuticals Inc.'s new Phase IIb top-line data showed that combining its investigational purine nucleoside phosphorlylate inhibitor, BCX4208, with a 300-mg dose of allopurinol could double the number of patients who achieve normal sUA levels. In the randomized, double-blinded, dose-response study, BCX4208 plus allopurinol was superior to allopurinol alone in patients with gout who had failed allopurinol alone.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription